Please ensure Javascript is enabled for purposes of website accessibility

CEO Says Sanofi Can Mass-Produce Hydroxychloroquine for COVID-19 Patients

By Eric Volkman – Apr 3, 2020 at 10:56AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Small studies using the decades-old malaria medication have suggested that it could speed up the recovery of those with the novel coronavirus.

Sanofi (SNY 2.25%) CEO Paul Hudson said that his company is ready, willing and able to produce a drug that seems to be efficacious in treating COVID-19, the disease that can result from the rapidly spreading SARS-CoV-2 coronavirus.

In an interview with Reuters published Thursday, Hudson claimed that Sanofi has the capability to make and distribute millions of doses of hydroxychloroquine if the drug is successful against COVID-19 in clinical trials. A more precise number was not provided.

Although hydroxychloroquine is a decades-old drug used chiefly to treat malaria -- which caused by a parasite, not a virus -- several limited-scale studies have indicated that it may be effective against COVID-19. But more testing will be required for a fuller understanding.

A coronavirus colony.

Image source: Getty Images

Recently, the Food and Drug Administration granted emergency use authorization for both hydroxychloroquine and chloroquine, an older related medication, to be used in the treatment of hospitalized COVID-19 patients. The FDA has not, however, formally approved either for use in treating COVID-19.

Several major pharmaceutical companies had pledged to supply large quantities of hydroxychloroquine and its relative before Hudson's latest utterances on the drug. Last month, Mylan relaunched its manufacture of the medication. At the time, Mylan said it planned to have it available by the middle of this month, and said it can produce as many as 50 million tablets -- enough to treat more than 1.5 million people.

Meanwhile, Teva Pharmaceutical has pledged to donate 10 million hydroxychloroquine tablets to treatment efforts, and Bayer promised to donate 3 million chloroquine tablets. 

In early trading on Friday, Sanofi shares were up by nearly 0.5%, in contrast to the broader S&P 500 market index, which at the time was down by about 1%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$40.07 (2.25%) $0.88
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.65 (5.10%) $0.42
Viatris Inc. Stock Quote
Viatris Inc.
MYL
Bayer Stock Quote
Bayer
BAYR.Y
$12.12 (3.07%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.